Non-alcoholic fatty liver disease (NAFLD) is a progressive disorder with increasing prevalence. There are currently no FDA approved treatments for the disease, and lifestyle improvements play a large role in disease management. A recent study conducted by Syneos Health shows that patients lack understanding of disease causes, implications, and prognosis. This is a large gap in the current standard of care which not only causes confusion and anxiety that impacts their ability to take charge of their own health but is also likely a limiting factor in clinical trial participation. Clinical trials should be incorporated into the current standard of care as an option for NAFLD patients while more robust clinical guidelines are developed. Sponsors have a significant opportunity to address important unmet needs for patients, even as their own research progresses to find new treatments.
